TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in child problem behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in carers' depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of decision-making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: left anterior cingulate volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax (maximum observed concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐infinity) (area under the plasma concentration curve from time 0 to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐infinity) (area under the plasma concentration curve from time 0 to the last measurable time point)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBS expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Morbidity of complication
Endpoint domain: Adverse events/effects
Primary endpoint: Constant shoulder scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNQ (shoulder function score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived thirst
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: superiority of emotional memory for temporal order
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalizations resulting from neutropenia and febrile neutropenia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prostate cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Reproducibility of range-of-motion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nephrin and podocalyxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total fiber consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RCAL gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in T. forsythia and P. gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma phytanic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact of Event Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median weekly sputum weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status (Chronic Respiratory Disease Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient preference for Flutter vs ACBT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Left ventricular function insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blurred vision reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MO measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of iris prolapse
Endpoint domain: Adverse events/effects
Primary endpoint: Stage 3 pupil billowing
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic efficacy (SPID(0‐3h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Body mass index percentile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid-base status (pH and bicarbonate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech-in-noise testing for the 50 per cent signal-to-noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of low birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative hip-knee-ankle (HKA) angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medial proximal tibial angle (MPTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized TKV growth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ADPKD-related events frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Event-Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Median survival duration
Endpoint domain: Mortality/survival
Primary endpoint: Tumor necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lowest recorded systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of citrate-related effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective tolerance toward LVL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Five-year overall relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Arterial oxygen tension (Pao2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial carbon dioxide tension (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Disease free survival (DFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Resident-reported worst pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month improvement in PHQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of depressive symptoms (PHQ reduced by 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADP-induced platelet aggregation function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hs-CRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: microscopic haematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for catheters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: withdrawal friction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPA receptor engagement duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spine bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine length increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rate of spironolactone therapy
Endpoint domain: Adverse events/effects
Primary endpoint: composite cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time to first incidence of UTI recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WORC scores at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difficulty completing rapid naltrexone induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per effect
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-reported organizational change
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical aspects of QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of days with asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with one or more exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prothrombin activation fragment 1.2 (F1.2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-dimer level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet aggregation in response to ADP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet aggregation in response to AA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular parameters (heart rate and blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sustained virological response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival abrasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal reductions in forearm blood flow in response to angiotensin II and phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Gestational Diabetes Mellitus (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: blood glucose responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hunger sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: White Matter Hyperintensity Volume (WMHV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial DFTs (defibrillation thresholds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivered energy at DFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak current
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of anemia (Hb <=10.5 g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion with severe anemia (Hb <7.0 g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gut permeability to polyethylene glycol 3350
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of leukocytosis greater than 11K
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak total leukocyte count (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for red blood cell transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Phototherapy requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Structured Assessment of Technical Skills score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale total reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in average morning and evening rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in diarrhea frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage time for which gastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean salivary cotinine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall quality of experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: willingness to participate again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VSS-SF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dizziness related impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nuclear staining of NFκB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8OHdG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum prostate-specific antigen (PSA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: mean time to successful puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean duration of radiation exposure to successful puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean numbers of attempts for successful puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PASP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-IR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Humoral nitrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak reactive hyperemia (RH) calf blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: within-person MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: between-group MID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival time (MST)
Endpoint domain: Mortality/survival
Primary endpoint: Mean value of serum somatostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 6-month survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Median survival time
Endpoint domain: Mortality/survival
Primary endpoint: Objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of glycerol test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saquinavir AUC(0,8 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saquinavir C(max)(0,8 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rifabutin AUC(0,24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean density at the time of maximum opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective visual evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of warmth during injection
Endpoint domain: Adverse events/effects
Primary endpoint: healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of reflux-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting miR‐92a levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial cholesterol efflux capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum squat jump power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weight of polyethylene wear particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of polyethylene wear particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shape of polyethylene wear particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to antidepressants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Free Interval (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subtherapeutic INRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oswestry functional disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma ADM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: magnitude of arterial oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage decline in hCG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage decline in progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tender-joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in swollen-joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in overall disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal breastfeeding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distal motor latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes